Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression.
about
Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarkerAngiogenesis in Ischemic Stroke and Angiogenic Effects of Chinese Herbal MedicineVascular Complications of Cancer ChemotherapyOverview and management of cardiac adverse events associated with tyrosine kinase inhibitorsr84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity inductionRole of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant ratsClinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertensionSorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial.Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitorsThe impact of microsomal prostaglandin e synthase 1 on blood pressure is determined by genetic background.Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.Cancer therapy-induced autonomic dysfunction in early breast cancer: implications for aerobic exercise training.Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.Anti-VEGF Cancer Therapy in Nephrology PracticeRenal actions of RGS2 control blood pressure.Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors.SFlt-1 elevates blood pressure by augmenting endothelin-1-mediated vasoconstriction in mice.Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease.Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trialA major role for the EP4 receptor in regulation of renin.Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia.Exercise training improves heart rate recovery in women with breast cancer.L-arginine supplementation abolishes the blood pressure and endothelin response to chronic increases in plasma sFlt-1 in pregnant rats.VEGF Receptor-2-Linked PI3K/Calpain/SIRT1 Activation Mediates Retinal Arteriolar Dilations to VEGF and Shear Stress.Increased Myogenic Reactivity of Uterine Arteries from Pregnant Rats with Reduced Uterine Perfusion PressureEndothelin: key mediator of hypertension in preeclampsia.Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition.Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humansTreatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors.Management of antiangiogenic therapy-induced hypertension.Anti-VEGF therapies in the cliniceNOS deficiency predisposes podocytes to injury in diabetes.Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics.Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies.Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients - an observational study
P2860
Q24595773-428B76CA-125D-4137-A26E-20B781ACAE18Q26747497-64E9AC6D-A63A-4DA3-864F-272A50E0493EQ26766269-7F5E1054-8793-44F4-9A76-F8707072BD48Q26865766-40DCC20A-477D-4584-9256-050F540F52DDQ27321768-84BCB1A5-92DC-47C4-B8F3-6781D42705ACQ28571017-D4D44BB7-EAA0-4591-832D-512D511A8F52Q28728389-CA6D22CB-C529-48A4-888B-CF1FFE599610Q30587082-051BEB07-2CC2-4F35-A249-3B5F3F67DD26Q30986269-59F7A76E-A021-404C-BBFD-2FAE3F50A843Q33684042-E483EB83-8756-4BFB-BD33-E2C38BE7D09EQ33698419-E5C61B17-E26F-4198-9A79-071B279F4EC0Q33720134-4DB61430-366B-419F-8F4E-C515507B7220Q33828690-5FDACC65-7F94-4734-A1CF-5F87C86B1B9FQ33978019-DC0CDE67-972E-49F0-8E58-90EBDDFA8113Q34013801-ABA165A8-FD9F-413B-8C5D-24CEFEFBA2FCQ34152125-1A7B5BFC-8C81-4AFF-9407-92E467822945Q34456993-68CB19A9-B596-4BA0-A064-545ACCCE537FQ34803030-7B985909-2A07-494A-93EC-DD3461D2BCAAQ35121861-1FF9A40A-C567-453B-B852-1A75E5BD6649Q35143007-98910DC2-4A92-4540-ABC3-171C4115B77AQ35187848-ADAB84F6-EA35-4797-96E5-AA2851FB874AQ35543233-9C440B04-3330-4C1C-9DF5-43FDA53D9A0DQ35599819-08258A5E-4DEC-4545-A2B5-0B130B6ED4B6Q35625070-CCCD71D8-FF89-4339-B6D1-BC098E5BF469Q35907911-00701A8F-5B00-4918-8F91-344F6A07F3A2Q35950303-CA52928D-2A1A-462B-B0F9-368807992496Q35980480-608A1559-FB88-4FA3-894A-1D7F60E3C426Q36006143-25DA0AAA-2C26-4FEE-B05B-EABEDF26791AQ36073225-81E7EE8D-686A-4C77-8236-176579784E65Q36094099-0F734059-EAC4-4BF3-91E5-A149CF8C9020Q36100725-6E5BCFD6-C071-4223-8A6C-1901FAE50B66Q36106439-34E9509D-B4D1-498F-8B8E-0259EA0D109EQ36170252-7F27A65D-419B-4F22-9C12-369C3EA88CA1Q36330281-2FE5C0E9-3D30-4895-AEB7-EB41071027D4Q36352132-1A8F4AB0-0CCE-4564-A2A7-21BEA92F5EF4Q36627125-47329863-E592-4F27-B348-AA8A5B75BEC7Q36630478-257FFC73-9233-4289-98A5-68403E830E6AQ36714379-D067C76D-4EEE-4C8E-AC37-2A4AAB9DCFD8Q36751861-E1E29510-FF02-4DEE-A760-35E4EB3F2F61Q36858624-D0C7C86A-D1C3-461C-8BB4-8AB5FBD97BFF
P2860
Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vascular endothelial growth fa ...... ric oxide synthase expression.
@en
Vascular endothelial growth fa ...... ric oxide synthase expression.
@nl
type
label
Vascular endothelial growth fa ...... ric oxide synthase expression.
@en
Vascular endothelial growth fa ...... ric oxide synthase expression.
@nl
prefLabel
Vascular endothelial growth fa ...... ric oxide synthase expression.
@en
Vascular endothelial growth fa ...... ric oxide synthase expression.
@nl
P2093
P2860
P1433
P1476
Vascular endothelial growth fa ...... ric oxide synthase expression.
@en
P2093
Andrew B Nixon
Carie S Facemire
Herbert Hurwitz
Robert Griffiths
Thomas M Coffman
P2860
P304
P356
10.1161/HYPERTENSIONAHA.109.129973
P407
P577
2009-08-03T00:00:00Z